https://www.live-feeds.com/feed/gilead-s-ibd-drug-eliminated-symptoms-for-patients-mid-stage-study-findsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/gilead-s-ibd-drug-eliminated-symptoms-for-patients-mid-stage-study-findshttps://www.live-feeds.com/feed/gilead-s-ibd-drug-eliminated-symptoms-for-patients-mid-stage-study-finds#u150078Fri, 23 Oct 2026 14:22:30 +0000Gilead Sciences reported that its experimental once-daily pill, emvistegrast, eliminated symptoms for patients and met its main goal in a mid-stage trial for ulcerative colitis. The oral treatment achieved stronger remission rates compared to a placebo and outpaced Entyvio in the mid-stage bowel disease study. These positive findings position the company to advance the asset into Phase 3 testing. The trial success strengthens the biotechnology firm's ongoing portfolio expansion into treatments for inflammatory and autoimmune conditions, drawing strong interest from industry analysts who v